Accordingly, CD133+ HCC cells were shown to have increased Akt signaling activity and resistance to chemotherapy drugs such as doxorubicin or 5-fluorouracil (FU), while an Akt inhibitor abolished the preferential survival of CD133+ HCC cells [44]. The gene discussed is PROM1; the disease is hepatocellular carcinoma.